PRECISION BIOSCIENCES INC Annual Report - Investor Summary

Unlock the insights into PRECISION BIOSCIENCES INC (Nasdaq: DTIL), a pioneering gene editing and therapy company. This summary distills key information from their latest annual report, offering retail investors a clear view of their strategic direction, financial health, and future prospects.

1. Business Overview

PRECISION BIOSCIENCES INC develops gene editing and gene therapy solutions. Their core technology, ARCUS, is a proprietary genome editing platform known for its high precision and efficiency. This past year, the company made a significant strategic shift by discontinuing its Cell Therapy operations. This move sharpens their focus on in vivo gene editing programs, aiming to streamline resources and accelerate development in key areas like PBGENE Hepatitis B Virus (HBV), PBGENE Duchenne Muscular Dystrophy (DMD), and PBGENE 3243.

Their business model relies heavily on strategic partnerships and licensing agreements. They collaborate with partners such as Novartis Pharma AG for discovery and development, and Imugene and TG Therapeutics for licensing. These partnerships are critical for funding, validating their technology, and expanding the reach of their therapeutic candidates. The company navigates a complex and evolving regulatory landscape for gene therapies and benefits from incentives like an Orphan Drug Tax Credit Carryforward, which provides tax advantages for developing treatments for rare diseases.

2. Financial Performance

The company reported "Sales Revenue Net" from partners like Novartis and Imugene in 2025, and from Prevail and TG Therapeutics in 2024. As a development-stage biotech company, they incurred substantial "Research and Development Expense" and "General and Administrative Expense" in both 2025 and 2024 to support their scientific and operational activities.

As of June 30, 2025, the market value of their publicly traded stock (excluding insider holdings) was approximately $47.1 million. With roughly 24.7 million shares outstanding as of March 5, 2026, this implies a share price of approximately $1.90 at that time. The company also actively managed its assets, including "Disposal Group Held For Sale" and "Equity Securities," on its books in both 2024 and 2025.

3. Risk Factors

Investing in PRECISION BIOSCIENCES carries several risks, typical for early-stage biotechnology companies:

• Clinical Development Risk: The success of their gene editing programs depends heavily on positive results from preclinical and clinical trials, which are inherently uncertain, lengthy, and expensive.
• Regulatory Approval Risk: Even with successful trials, regulatory approval from bodies like the FDA is not guaranteed, yet it is essential for commercialization. The complex and evolving regulatory environment significantly impacts development and approval pathways.
• Intellectual Property Risk: The gene editing space is highly competitive. The company's success depends on protecting its proprietary ARCUS technology and avoiding infringement on others' patents.
• Customer Concentration: They derive a notable portion of their revenue from a limited number of key partners. Losing a major partnership or a change in a partner's strategy could significantly impact PRECISION BIOSCIENCES' financial stability.
• Need for Future Funding: Given the high costs of R&D, the company will likely need substantial additional capital in the future. This could come from further debt, equity offerings (potentially leading to dilution), or new partnerships.
• Operational Scale: As a "Smaller reporting company" and "Non-accelerated filer," PRECISION BIOSCIENCES may have fewer resources and less robust internal controls than larger companies. This could increase operational risks and stock price volatility.
• Cell Therapy Discontinuation Costs: While strategic, winding down an entire operational segment can incur significant costs and asset write-downs, potentially reflecting previous difficulties or a need for substantial cost-cutting.
• High R&D Costs: As a gene editing company, PRECISION BIOSCIENCES faces inherently high research and development expenses, requiring continuous capital investment to advance its programs.

4. Management Discussion & Analysis (MD&A) Highlights

Results of Operations: Management's strategic pivot to discontinue Cell Therapy operations reflects a significant decision to optimize resource allocation and focus on the most promising in vivo gene editing pipeline assets. This shift should streamline operations and accelerate development in core areas. The company's "Sales Revenue Net" in 2025 and 2024 primarily came from strategic partnerships with entities like Novartis, Imugene, Prevail, and TG Therapeutics, which are critical for funding and validating their technology. As a development-stage company, it incurred substantial "Research and Development Expense" and "General and Administrative Expense" to advance its scientific programs and support its corporate infrastructure. They actively managed their portfolio through "Disposal Group Held For Sale" and "Equity Securities."

Liquidity and Capital Resources: The company's liquidity strategy relies heavily on a combination of strategic partnerships, debt instruments, and equity offerings. Public offerings in March 2024 and November 2025 secured necessary funding to advance research and development and extend the operational runway. They utilize financial instruments such as convertible debt (debt that can be converted into company stock under certain conditions, potentially leading to dilution for existing shareholders) related to the Imugene partnership. They also maintain revolving credit facilities with Banc of California and under a "Two Thousand Twenty Four Loan And Security Agreement," and hold a promissory note with Elo. A "Warrant Liability Noncurrent" also indicates warrant-related obligations. Given the inherently high costs of R&D in gene editing, management anticipates an ongoing need for substantial additional capital to fuel long-term development.

5. Future Outlook

PRECISION BIOSCIENCES' future outlook depends on successfully advancing its in vivo gene editing pipeline, particularly the HBV, DMD, and PBGENE 3243 programs. Key milestones include progressing these candidates through clinical trials, achieving positive data, and securing regulatory approvals. Continued success in forging and maintaining strategic partnerships remains critical for funding and commercialization. The company's ability to manage its high R&D costs and secure additional capital, including through further public offerings as demonstrated in 2024 and 2025, is paramount to its long-term viability and growth. The overall trend towards personalized medicine and advanced therapeutic modalities continues to shape their market, presenting both opportunities and challenges.

6. Competitive Position

The gene editing and gene therapy market is highly competitive, with large pharmaceutical companies and numerous smaller, innovative biotech firms. PRECISION BIOSCIENCES differentiates itself through its proprietary ARCUS gene editing platform. Competitors include companies developing alternative gene editing technologies (e.g., CRISPR, TALENs), gene therapies, and traditional small molecule or biologic drugs for similar indications. Their success will depend on the clinical efficacy, safety, and commercial viability of their therapeutic candidates compared to existing and emerging treatments.